TTC26 Activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of TTC26 via modulation of various intracellular signaling cascades. For instance, Forskolin and IBMX elevate the levels of cAMP, a pivotal secondary messenger that activates protein kinase A (PKA), leading to potential phosphorylation and enhancement of TTC26's activity. An increase in cAMP is also achieved by Rolipram and Anagrelide, both of which inhibit distinct phosphodiesterases, further promoting PKA signaling and possible enhancement of TTC26. Sildenafil and L-arginine, working through the nitric oxide signaling pathway, culminate in elevated cGMP levels, which may have a synergistic effect with cAMP pathways to augment TTC26's function. Similarly, A23187 raises intracellular calcium, a key regulator of numerous kinases, thus potentially phosphorylating and activating TTC26. PMA acts as a potent activator of protein kinase C (PKC), which can also lead to phosphorylation events that could enhance TTC26's activity.
These chemical activators also include molecules that modulate kinase signaling pathways, which play a critical role in cellular processes. LY294002, a PI3K inhibitor, may alter downstream AKT signaling, resulting in compensatory mechanisms that enhance TTC26. U0126 and SB203580, inhibitors of MEK1/2 andp38 MAP kinase, respectively, could lead to a rebalancing of signaling that favors the activation of TTC26 through alternative pathways. Thapsigargin, by disrupting calcium homeostasis, activates calcium-dependent kinases, potentially leading to the enhancement of TTC26's functional activity. Collectively, these activators, by affecting various signaling molecules and pathways, indirectly contribute to the regulation and enhancement of TTC26, without directly increasing its expression levels or acting as direct agonists. Through strategic inhibition and activation of key signaling intermediates, these compounds create a biochemical environment conducive to the enhanced activity of TTC26, thereby influencing its role in the cellular context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in cAMP levels. Elevated cAMP levels can result in the activation of protein kinase A (PKA), which can phosphorylate various proteins, potentially including TTC26, thereby enhancing its function. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, which increases cAMP by preventing its degradation. This rise in cAMP can activate PKA and could indirectly increase the activity of TTC26 by phosphorylation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, which elevates cAMP levels in various cell types, potentially enhancing TTC26 activity through PKA-dependent mechanisms. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase 3, leading to increased cAMP levels and activation of PKA. This pathway could indirectly phosphorylate and activate TTC26. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-arginine is a substrate for nitric oxide synthase, which produces nitric oxide that can activate guanylyl cyclase, increasing cGMP levels. Increased cGMP can indirectly enhance TTC26 activity via cross-talk with cAMP signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, which can activate calcium-dependent kinases. These kinases may then phosphorylate TTC26 or associated proteins, enhancing TTC26's functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can modulate the phosphorylation status of numerous proteins. Activation of PKC could lead to phosphorylation and subsequent activation of TTC26. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which can alter AKT signaling pathways. Inhibition of this pathway may lead to a compensatory upregulation or activation of TTC26 through alternative signaling mechanisms. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. Inhibiting MEK could lead to the activation of alternative signaling pathways that may enhance the functional activity of TTC26. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 could shift the signaling equilibrium to favor alternative pathways that may indirectly enhance the activity of TTC26. | ||||||